OM
LGND icon

Opaleye Management’s Ligand Pharmaceuticals LGND Stock Holding History

Opaleye Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-56,105
Closed -$2.35M – 30
2014
Q1 		$2.35M Sell
56,105
-88,165
-61% -$3.67M 1.74% 17
2013
Q4 		$4.86M Buy
+144,270
New +$4.7M 3.82% 8

Other funds holding LGND

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Opaleye Management's LGND Position: Q2 2014 in Review

Opaleye Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2014, closing a stake of 56,105 shares — an estimated $2.35M sold.

Opaleye Management first reported a position in LGND in Q4 2013 and held it in 2 quarters. The position peaked at $4.86M in Q4 2013. 192 funds tracked by Wall St. Rank hold LGND as of Q2 2014.

  • Opaleye Management reported no remaining Ligand Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Opaleye Management sold 56,105 Ligand Pharmaceuticals shares in Q2 2014, an estimated $2.35M.
  • Opaleye Management first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Opaleye Management's Ligand Pharmaceuticals position peaked at $4.86M in Q4 2013.
  • 192 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2014.

Based on Opaleye Management's 13F filing for Q2 2014, filed 14 Aug 2014.